Call us today 212-583-0100

ENZO Biochem Clinical Labs Subsidiary Announces Regional Services Contract with Horizon Blue Cross Blue Shield of New Jersey Agreement Covers the Traditional Networks Which Includes PPO and Indemnity Products

NEW YORK, NY, April 3, 2009   Enzo Biochem, Inc. (NYSE:ENZ), a biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications and laboratory services, today announced that its subsidiary, Enzo Clinical Labs, Inc., has been selected as a regional provider of medical laboratory services for Horizon Blue Cross Blue Shield of New Jersey.
 
“We are pleased to have been selected as a participating provider with one of the top regional health insurers in our service area,” said Kevin Krenitsky, MD, President of Enzo Clinical Labs, Inc. “As we continue to develop our strategic plan of broadening both our geographic reach as well as our test menu, being selected by such a well-respected insurer as Horizon will serve us well in achieving our goals.”
 
About Enzo Clinical Labs
 
Enzo Clinical Labs is a leading regional laboratory serving the greater New York/New Jersey area, which covers more than 20 million individuals.  The laboratory offers a full menu of state-of-the-art diagnostic procedures in areas such as chemistry, microbiology, hematology, blood banking as well as pathology and genetic testing. Enzo Clinical Labs is currently undergoing an expansion in the number and complexity of tests performed in-house. Our main location in Farmingdale, NY has the capacity to support the expanded testing and the impact from the new contract.  Enzo Labs maintains a network of more than 25 patient service centers, a satellite laboratory in New York City, and a full-service phlebotomy department.
           
About Enzo Biochem
Enzo Biochem is engaged in the research, development, manufacture and licensing of innovative health care products and technologies based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. Enzo’s Life Sciences division develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research among others.  Its catalog of over 33,000 products serves the molecular biology, drug discovery and pathology research markets. The Company's therapeutic division is in various stages of clinical evaluation of its proprietary immune regulation medicines for uveitis and Crohn's Disease and conducts pre-clinical research on several candidate compounds aimed at producing new mineral and organic bone, including technology that could provide therapy for osteoporosis and fractures, among other applications.  Enzo’s Clinical Labs division provides routine and esoteric reference laboratory services for physicians in the New York Metropolitan and New Jersey areas. Underpinning the Company’s technology and operations is an extensive intellectual property estate in which Enzo owns or licenses over 230 patents worldwide, and has pending applications for over 200 more. For more information visit our website www.enzo.com.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.